pioglitazone has been researched along with Alcohol Abuse in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwandt, ML | 1 |
| Diazgranados, N | 1 |
| Umhau, JC | 1 |
| Kwako, LE | 1 |
| George, DT | 1 |
| Heilig, M | 1 |
| Yeligar, SM | 1 |
| Mehta, AJ | 1 |
| Harris, FL | 1 |
| Brown, LAS | 1 |
| Hart, CM | 1 |
| Dieperink, E | 1 |
| Hauser, P | 1 |
| Dockter, K | 1 |
| Miranda, J | 1 |
| Evenson, M | 1 |
| Thuras, P | 1 |
| Blednov, YA | 1 |
| Benavidez, JM | 1 |
| Black, M | 1 |
| Ferguson, LB | 1 |
| Schoenhard, GL | 1 |
| Goate, AM | 1 |
| Edenberg, HJ | 1 |
| Wetherill, L | 1 |
| Hesselbrock, V | 1 |
| Foroud, T | 1 |
| Harris, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Proinflammatory Signaling in Alcohol Craving[NCT01631630] | Phase 2 | 16 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to The study was closed to recruitment due to feasibility problems.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 17.4172 |
| Placebo | 9.8121 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 13.7505 |
| Placebo | 8.1871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 19.0838 |
| Placebo | 10.5621 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 18.0838 |
| Placebo | 8.4371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 20.5838 |
| Placebo | 9.6871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 16.4172 |
| Placebo | 8.9371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 15.2505 |
| Placebo | 9.6871 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 19.2505 |
| Placebo | 8.9371 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 1 hour after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.5285 |
| Placebo | 9.1697 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the subject receiving an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 11.1285 |
| Placebo | 10.7947 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 2 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 11.9285 |
| Placebo | 9.0447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 3 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.5285 |
| Placebo | 10.5447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 4 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 12.1285 |
| Placebo | 10.5447 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 12.1285 |
| Placebo | 10.9197 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 6 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 9.9285 |
| Placebo | 9.6697 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 12.125 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 11.25 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10 |
| Placebo | 11.375 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.125 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.3333 |
| Placebo | 11.875 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.25 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.1667 |
| Placebo | 9.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01631630)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 10.6667 |
| Placebo | 9.625 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 2.8502 |
| Placebo | 4.5791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.3403 |
| Placebo | 1.1956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.2173 |
| Placebo | 1.2136 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.0507 |
| Placebo | 1.0706 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.0507 |
| Placebo | 1.6956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.884 |
| Placebo | 0.6956 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.884 |
| Placebo | 1.1125 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.884 |
| Placebo | 0.5706 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.2173 |
| Placebo | 1.8206 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 3.2897 |
| Placebo | 2.0706 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.3661 |
| Placebo | 3.2956 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7167 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.6366 |
| Placebo | 0.5912 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.3032 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.1366 |
| Placebo | 1.4937 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.1366 |
| Placebo | 1.1187 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.4699 |
| Placebo | 1.1228 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.6366 |
| Placebo | 0.9937 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 8.6366 |
| Placebo | 0.8687 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.9065 |
| Placebo | 0.9937 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.7503 |
| Placebo | 7.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 10 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.0837 |
| Placebo | 3.9372 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7503 |
| Placebo | 4.1872 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 17 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.7503 |
| Placebo | 4.0622 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.417 |
| Placebo | 3.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 24 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 5.917 |
| Placebo | 2.3122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.417 |
| Placebo | 2.6872 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 3 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 8.417 |
| Placebo | 5.9372 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 31 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 4.5837 |
| Placebo | 2.8122 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01631630)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 7.0837 |
| Placebo | 4.1872 |
1 trial available for pioglitazone and Alcohol Abuse
| Article | Year |
|---|---|
PPARγ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study.
Topics: Adult; Alcoholism; Animals; Craving; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Imagi | 2020 |
3 other studies available for pioglitazone and Alcohol Abuse
| Article | Year |
|---|---|
Pioglitazone Reverses Alcohol-Induced Alveolar Macrophage Phagocytic Dysfunction.
Topics: Alcoholism; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Ethanol; Humans; Lung; Macrophages, Alve | 2021 |
Reduced alcohol use in patients prescribed pioglitazone.
Topics: Alcohol Drinking; Alcoholism; Humans; Pioglitazone; Veterans | 2021 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibr | 2015 |